LYSOSOMOTROPIC FLUORINATED AMINE THERAPEUTIC AGENTS AND COMPOSITIONS CONTAINING THEM

Abstract: Compositions useful in the control of fertility, the inhibi­ tion of malignant cell growth, and the control of other dis­ eases which accumulate macrophages at the disease site, comprising a pharmaceutical carrier and lysosomotropic substance comprising a weakly basic amine of pK 4.5 to 9 containing at least one hydrophobic substituent or a peptide conjugate hydrolyzable by lysosomal enzymes to a biologi­ cally active substance. Certain of the amines, viz. those of formula: in which R is an alkyl substituent of from 8-30 carbon atoms, R₁ is hydrogen or alkyl, and R₂ is fluoroloweralkyl of 2-3 car­ bons, are novel and constitute another embodiment of the present invention. The compositions of the present invention are used to inhibit or alter the function of lysosome-bearing cells.

Description: TITLE OF THE INVENTION Lysosomotropic Detergent Therapeutic Agents SUMMARY OF THE INVENTION This invention relates to compositions useful in the control of fertility, in the inhibition of malignant cell growth, and in the control of other diseases which accumulate macrophages at the disease site. More specifically, it relates to novel chemical compositions and pharmaceutical formulations comprising a weakly basic amine having a pK of from 4.5 to 9 incorporating a hydrophobic moiety or a peptide conjugate which is hydrolyzed by lysosomal enzymes to an active substance. BACKGROUND OF THE INVENTION Lysosomotropic substances have been designated as substances which are selectively taken up by lysosomes regardless of their chemical nature or mechanism of uptake. It has been suggested that the property of lysosomotropism is useful in the preparation of therapeutic agents having useful biological properties. These substances can enter the lysosomes preferentially and exert their biological influence because of their own unique biological activity. They also can be coupled with active drugs and, following preferential uptake by lysosomes, can be hydrolyzed within the lysosome with release of the active drug at the target area. Thus, in one method of using the lysosomotropic agent DNA, a complex of DNA with the potent cytotoxic agent daunorubicin was formed. It was then found that the complex was preferentially taken up by the tumor cells and that the DNA was preferentially degraded by lysosomes leaving the active daunorubicin within the lysosome. A drawback of this particular method is that the toxic dose is very close to the therapeutic dose which makes the margin of safety very narrow. DESCRIPTION OF THE INVENTION The present invention is concerned with the inhibition of lysosome-bearing cells. More particularly, the present invention is concerned with new compositions and new pharmaceutical formulations which are useful in inhibiting the function of lysosome-bearing cells. Still more specifically, the present invention comprises novel pharmaceutical compositions comprising a pharmaceutical carrier and a lysosomotropic substance comprising (a) a weakly basic amine having a pK of from 5-8 and at least one hydrophobic substituent which is preferably an alkyl or unsaturated alkyl substituent having at -ieat·B - tabo'atoms or on a substituted alkyl substituent having at least 4 carbon atoms, or (b) a peptide amide coupled through the amide function with a biologically active material which is readily hydrolyzed by lysosomal enzymes either within the lysosome or at the outside surface of the lysosome-bearing cell. More specifically, the present invention comprises novel pharmaceutical compositions comprising a pharmaceutical carrier and (a) an amine compound having a pK of from 5-8 of the formula: EMI2.1 in which R is an alkyl or unsaturated alkyl substituent of from 8-30 carbons or a substituted alkyl substituent of from 4-30 carbons, R1 is hydrogen or alkyl, and R2 is an electron-withdrawing group to control the pK of the amine between 4.5 and 9 including fluoroalkyl such as trifluoroethyl or di fluoroethyl, carboxymethyl, cyanoethyl, hydroxy, methoxy, amino, alkylamino, and acylamidino; or (b) an alkyl-substituted, nitrogen-containing hetero cyclic compound having a pK of 4.9 to 9 of the formula: EMI3.1 wherein Z is either 0 or 1; R is alkyl or unsaturated alkyl, each of which con tains from--8-30 carbons, substituted alkyl of from 4-30 carbons, or a steroidal radical comprising 3-cholesteryl; R4 is acyl including -COOR1, -CORÚ, in which R is alkyl or aryl, arylsulfonyl including EMI4.1 or phosphoryl (-PO3); and R5 is selected from H or loweralkyl; or (c) a compound of the formula: M-N=A wherein N is an amine nitrogen, M is a masking group comprising a peptide substituent that can be hydro lyzed by any lysosomal enzyme comprising z-Gly-Phe, Gly-Phe, z-Arg-Arg, or Benzoyl-Arg, and A or N=A is an active therapeutic drug coupled with the peptide by way of an amide linkage. This A or N=A substi tuent is either an antifertility agent, a tumor inhibiting substance, an antibiotic substance, or an antiinflammatory steroid. More specifically, the present invention comprises novel lysosomotropic amine compositions of the formula: EMI4.2 wherein R is an alkyl substituent of from 8 to 18 carbons, R1 is hydrogen, alkyl, or substituted alkyl, and R2 is fluoroalkyl selected from difluoroethyl and trifluoroethyl. The compositions of the present invention are useful in selectively killing or altering the function of lysosome-bearing cells, and they are also useful as systems for the delivery of an active drug to the disease site where the active drug is released by lysosomal en zymitic hydrolysis. Thus, the compositions of this invention are useful as antifertility agents. As antifertility agents, the active principle--for example, a compound of the formula: EMI5.1 in which R, R1, and R2 are as defined previously--is in corporate into vaginal creams, jellies, or foams in a concentration of from 0.1t to 10%, preferably 1-10%. The formulation prepared in this manner is administered intravaginally and contact of the sperm with the composition of the present invention incorporates the active principle into the acrosome of the sperm cells, thus revering them infertile. The compositions of the present invention are also useful in inhibiting the growth of malignant tumor cells. For this purpose, the compositions of the present invention are administered either orally or by injection in a dosage schedule of 25-500 mg/kg/day. The compositions of the present invention are also useful in combatting infection caused by resistant microorganisms, which are sequestered within lysosomes and thus unavailable to attack by antibiotics. The lysosomotropic compositions of the present invention comprise an antibiotic incorporating a weakly basic amine group and a peptide linked to a carboxylic function of the antibiotic through an amide function. Such compositions are incorporated into the cell lysosome where they are hydrolyzed by lysosomal enzymes, thus releasing the active antibiotic principle to attack the infecting microorganism. Certain of the compositions of the present invention are useful in the treatment of inflammation. Thus a composition of an antiinflammatory steroid coupled to a lysosomally cleavable peptide through an amine function of the steroid is attracted to the site of inflammation, where it is cleaved by lysosomal enzymes at the site of inflammation thereby producing the desired antiinflammatory effect with reduced side effects. Alternatively, steroids such as cholesterol are rendered antiinflammatory by incorporating within them a lysosomotropic amine such as morpholine or trifluoroethylamine. The compounds of this invention can be administered either topically or systemically (i.e., intravenously, subcutaneously, intramuscularly, orally, rectally, by aerosolization, or in the form of sterile implants for long action. The pharmaceutical compositions can be sterile, injectable suspensions or solutions, or solid, orally administrable, pharmaceutically acceptable tablets or capsules; the compositions can also be intended for sublingual administration, or for suppository use. It is especially advantageous to formulate compositions in dosage unit forms for ease and economy of administration and uniformity of dosage. Dosage unit form" as a term used herein refers to physically discrete units suitable as unitary dosages for animal and human subjects, each unit containing a predetermined quantity of active material calculated to produce the desired biological effect in association with required pharmaceutical means. The low cost and ready accessibility of the compositions of this invention make them particularly promising for applications in veterinary medicine in which field their utilities are comparable to those in human medicine. A preferred embodiment of the present invention comprises a new class of compounds of the formula: EMI7.1 wherein R1 or R2 are hydrogen or alkyl, provided at least one of R1 and R2 is alkyl, alkenyl, or substituted alkyl containing from 8-18 carbons and R3 is a fluoroalkyl, preferably difluoro or trifluoroalkyl continuing from 2-3 carbons. These new compounds can be formulated into topical formulations for intravaginal administration as antifertility agents or may be formulated for oral or parenteral administration in accordance with the dose ranges given hereinabove. Compounds of this class are readily prepa-red by reaction of an amine of the formula: EMI7.2 with an anhydride or an ester of a fluorinated lower aliphatic carboxylic acid to produce an amide compound of the formula: EMI7.3 wherein n is an integer of from 1-8 inclusive, x is 0 or 1, and y is 2 or 3 provided that the sum of x and y is 3. The resulting amide compound is then reduced to the desired amine product by treatment with a reducing agent such as borane tn a suitable aprotic solvent such as tetrahydrofuran at a temperature of from OOC. to the reflux temperature of the reaction mixture for a period of from 1-24 hours. Examples of such amines are N-fluoroalkylamines such as l,l-dihydroperfluorooctylamine; N-dodecyl-2,2,2-trifluoroethylamine; N-octyl-2,2,2-trifluoroethylamine; N-decyl-2,2,2-trifluoroethylamine; N-hexadecyl-2,2,2-trifluoroethylamine; N-octadecyl-2,2,2-trifluoroethylamine; N-dodecyl-2,2-difluoroethylamine. Another embodiment of the present invention comprises a pharmaceutical formulation comprising an inert carrier and an alkyl-substituted, nitrogencontaining heterocyclic compound of the formula: EMI8.1 wherein R is alkyl, alkenyl, or substituted alkyl of from 8 to 18 carbons. Pharmaceutical formulations of this type are prepared by incorporating an effective amount of the nitrogen-containing heterocycle into a topical formulation such as a contraceptive jelly or foam. Examples of such heterocycles are N-alkyl pyridines such as N-nonyl, N-tridecyl, N-heptadecyl, and Nnonadecyl pyridine; 2-alkyl pyridines such as 2-nonyl, 2-tridecyl, 2-heptadecyl, and 2-nonadecyl pyridines; N-alkyl morpholines such as N-decyl, N-dodecyl, N-tetradecyl, N-hexadecyl, and N-octadecyl morpholines; and alkyl-substituted imidazoles such as N-dodecylimidazole. A still further embodiment of the present invention comprises a compound of the formula: M-N=A wherein M is a peptide substituent comprising z-gly-phe, gly-phe, z-arg-arg, or benzoyl-arg, and A or N=A is an active lysosome-inhibiting substance comprising a known therapeutic drug or an amino radical of the formula: EMI9.1 in which R is an alkyl or substituted alkyl substituent of from 8 to 18 carbons and R2 is fluoroalkyl or hydrogen. Compounds of the type: M-N=A are readily prepared by reaction of the selected amine with a selected peptide in the presence of a substance such as dicyclocarbodimide under anhydrous conditions. Compounds of this type are illustrated by the folding structural formulas in which the M substituent is a peptide described hereinabove: Pertide derivatives of antibiotic 593A and analogs as disclosed in U.S. Patent 3,718,651 of Gitterman et al. and U.S. Patent 3,840,542 of Shen et al.: EMI9.2 Peptide derivatives of a cephalosporin compound of the formula: EMI10.1 or an antiinflammatory steroid of the formula: EMI10.2 EXAMPLE 1 N-Dodecyl difluoroacetamide One equivalent difluoroethylacetate and one equivalent dodecylamine stirred at room temperature in acetonitrile 16 hours. The solvent is removed to give a white wax, which is chromatographed on silica gel in CHC13/EtOAc (15:1), Rf = 0.7. NMR (CDC13, g ) 7.2 b-s (lH); 5.9 t (2H) J=26; 3.35 m (2H); 1.3 s (20H); 0.9 m (3H). Other compounds prepared this way, with similar NMR, acceptable Mass Spectra and TLC: N-propyl-difluoroacetamide. EXAMPLE 2 N-Dodecyl-trifluoroacetamide Trifluoroacetic anhydride (21 ml; 1.5 equivalents) is added dropwise to a stirring solution of 17.9 g. dedecylamine (1 equivalent) and 13.5 ml. triethylamine (1 equivalent) in 100 ml. CH2C12 at OOC. over 30 minutes, and the mixture stirred at room temperature 30 minutes. It is washed with water, 1M H H3PO4, brine, dried over MgSO4, filtered, stripped to yield 26.01 g. product (96%). TLC in cyclohexane/EtAc (10:1) gives one spot at Rf - 0.5 and no starting material (Rf - 0.05). NMR (6, , CDCl3): 6.19 bs (lH); 3.30 q, J=4 (2H); 1.20 s (20 H); 0.92 m (3H). The following similar compounds were all preprepared in the same manner, all with similar NMR, acceptable microanalyses, mass spectra, and single spot on TLC: N-propyl-trifluoroacetamide, N-pentyl-trifluoroacetamide, N-octyl-trifluoroacetamide, N-decyl-trifluoroacetamide, N-hexadecyl-trifluoroacetamide ,- N-octadecyl-trifluoro- acetamide. EXAMPLE 3 N-Dodecyl-2,2,2-trifluoroethylamine A solution of 8 ml. H3 in THF (8 mM) is added dropwise to a solution of 1.12 g. (4 mM) dodecyl-trifluoroacetamide in 6 ml. THF at OOC. under N2. The mixture is refluxed 16 hours, cooled in ice, and 6 ml. concentrated HC1 added slowly. The THF is distilled off at atmosphere pressure, the mixture cooled in ice, and solid NaOH added slowly with cooling until alkaline to pH paper. The aqueous solution is then extracted three times with hexane. The combined organic layers are washed with water, dried over K2CO3, filtered, stripped to give 2.0 g. crude product. It is then chromatographed in cyclohexane/EtOAc (10:1) on silica gel (Rf = 0.4) to give 870 mg. oil which is distilled at 0.3 mM., b.p. 135 C., to give 405 mg. pure product, 38% yield. NMR (CDCl3, 6): 3.22 q, J=10 (2H); 2.79 m (2H); 1.40 s (20 H); 0.93 m (3H). IR shows no carbonyl bands. Other compounds made this way, all with similar NMR and other spectral data: N-octyl-2,2,2-trifluoroethylamine; N-decyl-2,2,2-trifluoroethylamine; N-hexadecyl-2 , 2, 2-trifluoroethylamine; N-octadecyl-2,2,2-trifluoxoethylamine; N-dodecyl-2,2-difluoroethylamine. EXAMPLE 4 N-Carbobenzoxy-glycyl-N-dodecyl phenylalanineamide Dodecylamine (924 mg.) in 20 ml. THF is added dropwise to a OOC. solution of 1.78 g. z-Gly-Phe and 1.02 g. DCC in 30 ml. THF under N2 and stirred at QOC. for 4 hours. The reaction mixture is filtered, the filtrate evaporated in vacuo to give 3.53 g. crude product, which was chromatographed on 100 go silica gel in CHC13/ EtOAc (2:1) to give 890 mg. product (34%), NMR (CDCl3, d): 7.7 m (lH); 7.3 d (10 Hz); 6.6 m (lH); 6.2 m (lH); 5.2 s (2H); 4.8 m (lH); 3.9 d, J=6 Hz {2H); 3.1 m (4H); 1.3 bs (20 H); 0.9 m (3H). Other compounds made this way with similar spectral data: N-carbobenzoxy-glycyl-N-dodecyl-N-2 2, 2-trifluoro- ethyl-phenylalanineamide. EXAMPLE 5 N-Dodecyl Imida:ole One equivalent imidazole and 1.2 equivalents bromododecane are stirred at 2000C. under N2 for 1 hpur. The reaction mixture is taken up in base, extracted with CH2Cl2. The organic layer is dried over X2CO3, filtered, stripped to give yellow-brown oil which is chromatographed to give clear oil which is distilled-under vacuum to give pure product. NMR; ( g , CDCl3): 7.45 s (1H); 7,0 d, J=9 (2H); 3.92 t J=7 (2H); 1.3 s (20 H); 0.9 m (3H). EXAMPLE 6 Contraceptive Formulati?ns A suitable formulation is prepared by mixing the lysosomotropic amine and other ingredients employed in the following proportions (in percentages): Benzyldimethyl [2-[2-(p-1,1,3,3-tetramethyl- butylphenoxy) ethoxyl ethyl] ammonium chloride (benzethonium chloride, U.S.P.) .............. 0.2 N-dodecyl-2 , 2, 2-trifluoroethylamine B .0 Myristic acid ...................................... 2.0 Stearic acid ...................................... 4.0 Triethanolamine ................................... 2.0 Glyceryl monosterate ............................... 3.0 Polyoxyethylene (20) sorbitan mono-oleate ........... 3.0 Polyoxyethylene (20) sorbitan monolaurate .......... 3.0 Polyvinylpyrrolidone ................................ 1.0 Polyethylene glycol (average molecular weight, 600).. 1.4 Deionized water .................................... 72.4 100.0 The procedure is repeated using as the active ingredient, in place of N-dodecyl-2,2,2-trifluoroethylamine, a similar percentage of any of the compounds prepared in accordance with Examples 3, 4, and 5. Other similar formulations are prepared by repeating the procedure using, in place of N-dodecyl-2,2,2trifluoroethylamine, an identical amount of one of the following compounds: N-alkyl pyridines such as N-nonyl, N-tridecyl, N-heptadecyl, and N-nonadecyl pyridine; 2alkyl pyridines such as 2-nonyl, 2-tridecyl, 2-heptadecyl, and 2-nonadecyl pyridines; N-alkyl morpholines such as N-decyl, N-dodecyl, N-tetradecyl, N-hexadecyl, and Noctadecyl morpholines, and alkyl-substituted imidazoles such as N-dodecylimidazole. EXAMPLE 7 Capsule Formulation N-dodecyl-2,2,2-trifluoroethylamine 25 25 gm. Stearic Acid (U.S.P. triple pressure) ........... 125 gm. Pluronic F-68 ................................. 7.5 gm. Corn Starch ............................ 125 gm. The stearic acid and pluronic are united in a vessel and melted using a water bath at 60-650C. The heating is discontinued and the N-dodecyl-2,2,2-trifluoroethylamine is dispersed into the mixture and the corn starch is added with stirring which is continued until the mixture cools to ambient temperature. The mixture is reduced to granules by screening and placed in a number 0 hard gelatin containing 282.5 mg. of total solids and 25 mg. of N-dodecyl-2,2,2-trifluoroethylamine per capsule. This procedure is repeated using as the active ingredient any of the compounds prepared in accordance with Examples 3, 4, and 5, with resultant production of pharmaceutical formulations of the present invention. Other formulations are prepared by repeating the procedure using the same amount of one of the following heterocyclic compounds: N-alkyl pyridines such as N-nonyl, N-tridecyl, N-heptadecyl, and N-nonadecyl pyridine; 2-alkyl pyridines such as 2-nonyl, 2-tridecyl, 2heptadecyl, and 2-nonadecyl pyridines; N-alkyl morpholines such as N-decyl, N-dodecyl, N-tetradecyl, N-hexadecyl, and N-octadecyl morpholines, and alkyl-substituted imidazoles such as N-dodecylimidazole.

Claims: WHAT IS CLAIMED IS: 1. A pharmaceutical composition comprising a pharmaceutical carrier and a lysosomotropic substance comprising a weakly basic amine of pK 4.5 to 9 containing at least one hydrophobic substituent or a peptide conjugate hydrolyzable by lysosomal enzymes to a biologically active substance. 2. A pharmaceutical composition comprising a pharmaceutical carrier and a lysosomotropic substance comprising: (a) an amine compound having a pK of from 4.5-9 which has the formula: EMI16.1 in which R is an alkyl or unsaturated substituent of from 8-30 carbon atoms or a substituted alkyl substi tuent of from 4-30 carbon atoms, R1 is hydrogen or alkyl, and R2 is an electron-withdrawing group to control the pK of the amino between 4.5 and 9, in cluding fluoroalkyl, carboxymethyl, cyanoethyl, hydroxy, methoxy, amino, alkylamino, and acylamidino; (b) an alkyl substituted heterocyclic compound of the formula: : EMI16.2 EMI17.1 wherein z is either 0 or 1; R is alkyl or unsaturated alkyl, each of which con tains from 8-30 carbons, substituted alkyl of from 4-30 carbons, or a steroidal radical comprising 3-cholesteryl; R4 is acyl including -COOR1, -COR1 in which R1 is alkyl or aryl, arylsulfonyl including EMI17.2 or phosphoryl (-PO3); and R is selected from H or loweralkyl; or (c) a compound of the formula: M-N=A wherein M is a peptide substituent selected from gly-phe, z-gly-phe, z-arg-arg, and benzoyl-arg, and A or N=A is an active therapeutic drug moiety coupled with the peptide by means of an amide linkage. 3. A composition according to Claim 2 comprising a pharmaceutical carrier and a lysosomotropic amine substance having a pK of from 4.5-9 of the formula: EMI18.1 in which R is an alkyl substituent of from 8-30 carbon atoms, R1 is hydrogen or alkyl, and R2 is fluoroloweralkyl of 2-3 carbons. 4. A composition according to Claim 2 comprising a pharmaceutical carrier and a lysosomotropic alkyl substituted heterocyclic compound of the formula: EMI18.2 wherein R is alkyl, alkenyl, or substituted alkyl of from 8 to 18 carbons. 5. A composition according to Claim 2 comprising a pharmaceutical carrier and a compound of the formula: M-N=A wherein M is a peptide substituent selected from gly-phe, z-gly-phe, z-arg-arg, and benzoyl-drg; and A or N=A is an active therapeutic drug moiety coupled with the peptide by means of an amide linkage. 6. A novel lysosomotropic amine detergent having a pK of 5-8 of the formula: EMI19.1 in which R is an alkyl substituent of from 8-30 carbon atoms, R1 is hydrogen or alkyl, and R2 is fluoroloweralkyl of 2-3 carbons. 7. A method for inhibiting or altering the function of lysosome-bearing cells which comprises contacting said cells with a pharmaceutical composition comprising a pharmaceutical carrier and a lysosomotropic substance comprising a weakly basic amine of pK 4.5 to 9 containing at least one hydrophobic substituent or a peptide conjugate hydrolyzable by lysosomal enzymes to a biologically active substance.

Inventors: FIRESTONE, RAYMOND A.
Applicants: MERCK & CO. INC.
Application year: 1979
Main classification: A61K31
IPC codes: A61K31, C07J43, C07D501, A61P31, C07K5, A61P35, C07D521, A61K47, A61K38